



ADVITECH ANNOUNCES ITS INTENTION TO PROCEED TO FINANCING BY WAY OF PRIVATE PLACEMENTS AND THE APPOINTMENT OF AN INVESTORS' RELATIONS CONSULTANT

TSX VENTURE EXCHANGE : AVI

FOR IMMEDIATE RELEASE

QUEBEC – MARCH 1, 2007 – Advitech inc. (“Advitech” or the “Corporation”) (TSX Venture: AVI) announced today its intention to complete a financing by way of private placements as well as the appointment of Mr. Serge Comeau as investors' relations consultant.

PRIVATE PLACEMENTS

This proposed financing would be comprised of two tranches. The first tranche would consist of a placement of units at a price of \$0.12 per unit, for a minimum amount of \$250,000 and a maximum amount of \$500,000, and the second tranche would consist in the issuance of convertible debentures for a minimum amount of \$350,000 and a maximum amount of \$600,000. This financing would be conducted in accordance with Regulation 45-106 respecting prospectus and registration exemptions.

Each unit will be comprised of one common share of the Corporation and one common share purchase warrant entitling its holder to purchase one additional common share at the price of \$0.20 per share during the first year from the closing date and at a price of \$0.25 until the second anniversary of the closing.

The convertible debentures, offered in \$1,000 tranches, will bear interest at an annual rate of 12 % payable monthly. The capital of debentures will become due on January 31, 2012 and may be repaid by the Corporation at any time without penalty. From the closing date until August 31, 2007, interest on the debentures will be capitalized, added to the debenture capital and paid at the end of the term. The debentures are also convertible into common shares of the Corporation at a conversion price of \$0.15 per common share until January 31, 2008 and \$0.20 per common share until January 31, 2009. In accordance with the policies of the TSX Venture Exchange, the conversion price will then increase by 10% for each subsequent year until the end of the term.

Closing should take place on or about March 16, 2007 but no later than March 31, 2007.

Advitech recently completed a \$500,000 convertible debenture private placement with Capital Financière agricole inc.

APPOINTMENT OF AN INVESTOR'S RELATIONS CONSULTANT

Additionally, Advitech Inc. announced today that it has retained the services of Mr. Serge Comeau to provide the Company with strategic investor relations services. Advitech will pay a monthly retainer fee of 3,000\$ to Mr Comeau for its services. Mr. Comeau will also be granted 100,000 options subject to the Company's board approval and in accordance with the policies of the TSX Venture Exchange, the options will vest in four (4) equal quarterly tranches. The contract is for an initial term of twelve (12) months.

About Advitech Inc.

Advitech is a health sciences and technology company with a mission to discover and commercialize proprietary and evidence-based natural health products. Effective and safe, these products play a role in the prevention of Immune-Mediated Inflammatory Disorders (IMID), such as psoriasis and inflammatory bowel disease. Advitech's common shares are listed on the TSX Venture Exchange under the symbol AVI. The number of common shares outstanding is 61,247,318. The NEW Dermylex™ website is now online at www.dermylex.ca.

About Dermylex™

Dermylex™ developed by Advitech, is an oral natural health product relieving mild-to-moderate psoriasis symptoms. Two clinical trials, one of them multi-center, double-blind and placebo-controlled, for 112 days and on 84 patients, clinically proved the efficacy and safety of Dermylex™ for that type of psoriasis. Dermylex™ is currently available in Canada. For more information, please visit the www.dermylex.ca website.

-30-

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Advitech Inc.
Renaud Beauchesne
President and Chief Executive Officer
418-686-7498
info@advitech.com
www.advitech.com